Fennec Pharmaceuticals Inc.

FENC · NasdaqCM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders14.1%

Institutions54.3%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$44.64M	$47.54M	$21.25M	$1.53M	–	–	$0	$0	$0	$0
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	–	–	$1.26M	$86000	–	–	–	–	–	–
Revenue left after subtracting the direct cost of producing goods or services — how efficiently the core business converts sales into profit before overhead.	–	–	$19.99M	$1.45M	–	–	–	–	–	–
Gross profit as a percentage of revenue.	–	–	94.1%	94.4%	–	–	–	–	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$6.28M	$2.57M	-$12.77M	-$22.59M	-$17.22M	-$17.89M	-$13.01M	-$10.41M	-$6.95M	-$2.87M
Operating income as a percentage of revenue.	-14.1%	5.4%	-60.1%	-1471.6%	–	–	–	–	–	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$9.74M	-$436000	-$16.05M	-$23.71M	-$17.35M	-$18.11M	-$12.78M	-$9.89M	-$7.05M	-$2.79M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-0.34	$-0.02	$-0.60	$-0.90	$-0.67	$-0.76	$-0.64	$0.00	$0.00	$0.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-0.34	$-0.02	$-0.60	$-0.90	$-0.67	–	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$36.79M	$26.63M	$13.27M	$23.77M	$21.10M	$30.34M	$13.65M	$22.78M	$28.26M	$3.93M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$70.55M	$44.95M	$26.86M	$26.94M	$22.41M	–	$14.15M	$22.95M	$28.40M	$3.97M
Everything the company owes — debt, unpaid bills, and other obligations.	$35.08M	$50.82M	$38.49M	$29.51M	$6.64M	–	$2.27M	$1.64M	$1.64M	$402000
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$35.47M	-$5.87M	-$11.62M	-$2.57M	$15.77M	–	$11.88M	$21.31M	$26.76M	$3.57M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$12.47M	$26.98M	-$17.14M	-$18.06M	-$14.22M	-$15.60M	-$9.06M	-$7.83M	-$3.64M	-$2.12M

	You	Peer avg
Revenue Growth	+85.2%	–
ROE	-18.6%	-55.3%

Fennec Pharmaceuticals Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison